pTau-217 (AD-Detect)
A blood biomarker of Alzheimer's-related brain pathology — specifically tau protein phosphorylation associated with amyloid burden.
One of the most significant advances in blood testing in years. Until recently, detecting Alzheimer's pathology required a PET scan or spinal tap. pTau-217 correlates strongly with brain amyloid and can detect changes years before symptoms.
Optimal ranges, root causes, and the complete correction protocol — nutrition, supplements, lifestyle, hormones and peptides — plus 100+ other markers.
Unlock everything — $10/mo →📚 Palmqvist S et al., JAMA 2020 — plasma p-tau217 for Alzheimer's discrimination. Livingston G et al., Lancet 2024 — modifiable dementia risk factors.
🩸 Test your pTau-217 (AD-Detect)
Order directly through Marek Diagnostics — no doctor's visit needed, drawn at any Quest location in the US. Code CAMERON applies 10% off automatically.
Order this test — 10% off → Browse all 102 markers →What pTau-217 (AD-Detect) is usually tested alongside
On its own, one marker is a data point. These panels include pTau-217 (AD-Detect) plus the markers that make it interpretable — each names every test, why it is on the list, and loads the whole set into your cart in one click at 10% off.
includes this + 8 more markers — Family history of dementia, noticeable memory change, or you want the earliest possible read on brain health while there's still time to act.
Would you feel it? Symptoms pTau-217 (AD-Detect) helps explain
People rarely search for a marker — they search for how they feel. These are the complaints where this marker is worth checking, and whether it is a first-line test or a follow-up once the obvious causes are ruled out.
Why your pTau-217 (AD-Detect) might be wrong
Most abnormal results are interference, not disease. These are the things that measurably move this specific marker — check them before you change anything. Each one says whether the number is wrong and should be repeated, badly timed and should be redrawn, or real with a cause worth explaining.
Both affect plasma concentrations of the tau and amyloid markers independently of brain pathology — a real limitation of blood-based neurodegeneration testing.
Interpret with kidney function in mind, and with a clinician.
These assays are sensitive to tube type, processing delay and freeze-thaw.
Use a lab that runs the validated workflow. Do not compare across platforms.
What pTau-217 (AD-Detect) means in combination
A single marker tells you a little. Combinations tell you the story — these are the named patterns this marker takes part in, and what each one points at.
Genuinely reassuring, and worth stating because the genotype alone frightens people. ε4 raises lifetime risk; a normal pTau-217 says the amyloid pathology those risk figures describe is not currently detectable. Many ε4 carriers never develop dementia.
Put the effort into the fourteen modifiable risk factors — hearing, blood pressure, glucose, exercise, sleep, alcohol, social connection. They account for far more than the genotype does, and unlike it they respond.
What to test next
Markers rarely answer alone. These are the ones that put pTau-217 (AD-Detect) in context — each with its own full breakdown.
Frequently asked questions
Assay- and lab-specific reference values Ranges vary by laboratory and assay — always compare to the range printed on your own report.
Optimal ranges, root causes and the full correction protocol are available inside Coach Cam's Peptide Academy.
See the full breakdown inside the Academy.
See the full breakdown inside the Academy.
You can order pTau-217 (AD-Detect) directly through Marek Diagnostics without a doctor's visit — drawn at any Quest Diagnostics location in the US. Code CAMERON applies 10% off automatically.